← All trials
NCT05199493
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 27, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Mar 31, 2023
- First posted
- Jan 20, 2022
- Last posted
- Jul 13, 2022
- Enrollment
- 64
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MunsterLead sponsor
- German Research FoundationCollaborator
- University of MunsterStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.